摘要
目的本研究对奥沙利铂联合替吉奥（SOX）或奥沙利铂联合卡培他滨（XELOX）治疗进展期胃癌的有效性及安全性进行荟萃分析,以期更有效地指导临床用药。方法在CNKI、万方、维普、PUBMED数据库中,检索SOX和XELOX 2组方案治疗进展期胃癌的随机对照临床研究（randomized controlled trials,RCT）,按照JADAD质量计分法对所纳入的每篇文献逐篇进行方法学质量评估;荟萃分析采用Rev Man 5.2.0（Cochrane-information Management System）进行系统评价,评价内容为2种化疗方案的有效性（即临床缓解率,PR＋CR）与安全性。结果共有8个临床研究纳入本系统评价,共计603例中国进展期胃癌患者,其中应用SOX方案化疗患者293例,应用XELOX方案治疗患者310例。分析结果显示2种方案治疗进展期胃癌患者的有效率无显著差异（OR=1.19,95%CI：0.86-1.64,P=0.29）。就不良反应而言,SOX方案口腔黏膜炎的发生率明显高于XELOX方案（OR=2.29,95%CI：1.74~4.89,P〈0.0001）,其他不良反应差异无明显统计学意义。总体看来,SOX方案与XELOX方案不良反应发生率无差异（OR=0.88,95%CI：0.66~1.19,P=0.41）。结论在中国进展期胃癌患者的临床治疗中,SOX方案在临床缓解率方面与XELOX方案不相上下,但其口腔黏膜炎的发生率明显高于XELOX方案。
Objective To compare clinical outcome and adverse reactions between the regimens SOX and XELOX for chemotherapy of advanced gastric carcinoma in Chinese population.Methods The original articles on randomized controlled trials （ RCTs） comparing the chemotherapy of SOX and XELOX in Chinese patients with advanced gastric carcinoma were recruited from the PUBMED, WANFANG, VIP and CNKI databases.The quality of the selected trials were assessed by JADAD method.Meta-analysis about the efficacy and safety of the two chemotherapy methods was performed by Rev Man 5.2.0 software （ Cochrane-information Management System） .Results Eight RCT studies were recruited in our work, including 293 patients in the SOX treatment group and 310 in the XELOX treatment group.The analysis results showed that there was no significant difference in the effect of the two chemotherapy methods （OR=1.19, 95%CI：0.86-1.64,P=0.29）, and referred to the safety evaluation, the stomatitis （OR=2.29, 95%CI：1.74-4.89, P〈0.0001） incidence in SOX treatment group was higher than XELOX treatment group, and in total, there was no significant difference in adverse reaction incidence of the two chemotherapy methods（OR =0.88, 95%CI： 0.66-1.19, P =0.41）.Conclusion In the chemotherapy of advanced gastric carcinoma in Chinese population, there is no significant difference in clinical response rate between SOX and XELOX, and the stomatitis incidence of SOX is significantly higher than that of XELOX.
出处
《中国生化药物杂志》
CAS
2015年第5期56-60,共5页
Chinese Journal of Biochemical Pharmaceutics
基金
陕西省科技研究发展计划项目(2013KJXX-91)
